Lead Product(s): SACT-1
Therapeutic Area: Oncology
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 26, 2020
Net proceeds from the offering will fund the continued research and development of its leading therapeutic candidates (including SACT-1 and ALS-4) into their respective clinical phases.